Compounds and methods for inhibiting fascin
US-9573946-B2 · Feb 21, 2017 · US
Imipramine for use as an inhibitor of Fascin1 overexpression
US12343349B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12343349-B2 |
| Application number | US-201917281084-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 22, 2019 |
| Priority date | Sep 28, 2018 |
| Publication date | Jul 1, 2025 |
| Grant date | Jul 1, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention refers to Imipramine for use as inhibitor of fascin1 overexpression, preferably said overexpression of fascin1 is associated to cancer, and more preferably to colorectal cancer. It also refers to a method for the treatment of cancer mediated by fascin1 comprising administering to a subject in need thereof an effective amount of imipramine, and more preferably to colorectal cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for the treatment of cancer mediated by fascin1 comprising administering to a subject in need thereof an effective amount of imipramine. 2. The method according to claim 1 , wherein the fascin1 is overexpressed. 3. The method according to claim 1 , wherein the cancer is colorectal cancer. 4. The method according to claim 3 , wherein the colorectal cancer is serrated adenocarcinoma. 5. The method according to claim 3 , wherein the colorectal cancer is selected from gastrointestinal stromal tumors, leiomyosarcomas or melanomas. 6. The method according to claim 3 , wherein the colorectal cancer is metastatic colorectal cancer.
Assignees
Inventors
- Conesa Zamora Pablo
- Perez Sanchez Horacio
- Luque Fernández Irene
- Montoro García Silvia
- Alburquerque Gonzalez Begoña
- Campioni Rodrigues Priscila
- García Solano José
- Bernabé García Angel
- Nicolás Villaescusa Francisco José
- Bernabé García Manuel
- Cayuela Fuentes Maria Luisa
- Ruiz Sanz Javier
- Martínez Herrerías Jose Cristobal
- Salo Tuula
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12343349B2 cover?
- The present invention refers to Imipramine for use as inhibitor of fascin1 overexpression, preferably said overexpression of fascin1 is associated to cancer, and more preferably to colorectal cancer. It also refers to a method for the treatment of cancer mediated by fascin1 comprising administering to a subject in need thereof an effective amount of imipramine, and more preferably to colorectal…
- Who is the assignee on this patent?
- Fundacion Univ San Antonio, Fundacion Para La Formacion E Investig Sanitarias, Univ Granada
- What technology area does this patent fall under?
- Primary CPC classification A61K31/55. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).